A tissue treatment device that can participate in the biotech-driven immuno-oncology fervor of the last few years may sound too good to be true. That's precisely the case being made by long-short hedge fund Kerrisdale Capital Management LLC, which has issued a report critical of the science behind early stage Pulse Biosciences Inc. and holds a short position betting against it.